Skip to content
Triangle logo TriangleGet started
← Study library

NCT01245764 · REGISTRY CONDITION SEARCH

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2018-11-14

The study is designed to determine the safety, tolerability and immunogenicity of a 3-dose regimen of GARDASIL™ administered to healthy females between 9 and 26 years of age, in Sub-Saharan Africa. Data from the current study are needed in order to complement existing extensive safety data from the GARDASIL™ clinical trials program, and confirm that GARDASIL™ may be administered safely and will induce immune responses in populations from and living in Sub-Saharan Africa, as GARDASIL™ has not previously been studied in this region of the world.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants Who Seroconvert to Human Papillomavirus (HPV) Type 6

→

outcome · POSTED

Number of Participants Who Seroconvert to HPV Type 11

→

outcome · POSTED

Number of Participants Who Seroconvert to HPV Type 16

→

outcome · POSTED

Number of Participants Who Seroconvert to HPV Type 18

→

outcome · POSTED

Number of Participants With Injection-site Adverse Experiences

→

outcome · POSTED

Number of Participants With Elevated Temperature (Oral Temperature >=100 °F)

→

outcome · POSTED

Number of Participants With Serious Adverse Experiences

→

outcome · POSTED

Geometric Mean Titer (GMT) of Anti-HPV Type 6 Antibody

→

outcome · POSTED

GMT of Anti-HPV Type 11 Antibody

→

outcome · POSTED

GMT of Anti-HPV Type 16 Antibody

→

outcome · POSTED

GMT of Anti-HPV Type 18 Antibody

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria : * Healthy subjects who are native to and living in a participating Sub-Saharan African country. * Subject agrees to provide study personnel with a primary telephone number as well as an alternate telephone number for follow-up purposes. If potential subject does not have a telephone number, the subject must provide an address at which he or she may be contacted. * Post-pubertal female subjects must not be pregnant * Subjects who are sexually active must agree to use effective contraception or remain abstinent through Month 7 of the study. * Subjects who have not yet had sexual intercourse must either agree to remain abstinent through Month 7 of the study, or if they become sexually active during the vaccination phase of the study, to use effective contraception through Month 7. * Subjects who have had sexual intercourse in the two weeks prior to enrollment must have been using effective contraception as defined above. (Emergency contraception is not considered effective contraception for enrollment in the study.) Exclusion Criteria : * Subject is pregnant as determined by a positive pregnancy test * Subject has had a temperature ≥ 37.8 °C or ≥ 100 °F within 24 hours prior to the first injection. * Subject is currently enrolled in another clinical study of an investigational agent or agents. * Subject has a history of known prior vaccination with a HPV vaccine, or was previously enrolled in an HPV vaccine study and received either active agent or placebo. * Subject has received any inactivated vaccine within 14 days prior to enrollment or any live vaccine within 21 days prior to enrollment. * Subject has a history of severe allergic reaction to any agent (e.g., swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention. * Subject has known allergy to any vaccine component, including aluminum, yeast or BENZONASE™ (nuclease, Nycomed™ \[used to remove residual nucleic acids from this and other vaccines\]). * Subject has received any immune globulin preparation or blood-derived products within the 6 months prior to the first injection, or plans to receive any such products during the course of the study. * Subject has a history of splenectomy, known autoimmune disorder (e.g., systemic lupus erythematosus, rheumatoid arthritis), or is receiving immunosuppressives (e.g., substances or treatments known to diminish immune response such as radiation therapy, administration of antimetabolites, antilymphocytic sera, systemic corticosteroids). Individuals who have received periodic treatments with immunosuppressives, defined as at least 3 courses of systemic corticosteroids each lasting at least 1 week in duration for the year prior to enrollment, will be excluded. Subjects using topical steroids (i.e., inhaled or nasal) will be eligible for vaccination. * Subject is immunocompromised or has been diagnosed as having Human Immunodeficiency Virus (HIV) infection * Subject has known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections. * Subject has known sickle cell anemia disease, active malaria or active tuberculosis. * Subject has any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives. * Subject has a history of recent or ongoing alcohol or other drug abuse. * Female subject has a prior history of abnormal Pap test showing squamous intraepithelial lesion (SIL), atypical squamous cells of undetermined significance (ASC-US), atypical squamous cells, cannot rule out a high grade lesion (ASC-H), or biopsy showing cervical intraepithelial neoplasia (CIN) or worse. * Subject has any prior history (or at Day 1) of genital warts or treatment for genital warts. * Subject with \>4 lifetime sexual partners. * Subject has undergone hysterectomy with removal of the cervix. * Subject plans to permanently relocate from the area prior to the completion of the study or to leave for an extended period of time when study visits would need to be scheduled.
healthy Volunteers
true
maximum Age
26 Years
minimum Age
9 Years
sex
FEMALE
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
    intervention Names
    1. Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
    label
    GARDASIL™ 9 to 12 Years Old
    type
    EXPERIMENTAL
  2. description
    GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
    intervention Names
    1. Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
    label
    GARDASIL™ 13 to 15 Years Old
    type
    EXPERIMENTAL
  3. description
    GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
    intervention Names
    1. Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
    label
    GARDASIL™ 16 to 26 Years Old
    type
    EXPERIMENTAL
  4. description
    Placebo to GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. After database lock and unblinding for study Phase A, participants will have the option to receive GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase B.
    intervention Names
    1. Biological: Placebo
    label
    Placebo 9 to 12 Years Old
    type
    PLACEBO_COMPARATOR
interventions
  1. arm Group Labels
    1. GARDASIL™ 13 to 15 Years Old
    2. GARDASIL™ 16 to 26 Years Old
    3. GARDASIL™ 9 to 12 Years Old
    name
    Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Placebo 9 to 12 Years Old
    name
    Placebo
    type
    BIOLOGICAL
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
TRIPLE
who Masked
  1. PARTICIPANT
  2. INVESTIGATOR
  3. OUTCOMES_ASSESSOR
primary Purpose
PREVENTION
Enrollment
count
250
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Seroconversion was defined as achieving an anti-HPV Type 6 competitive Luminex Immunoassay (cLIA) level of \>=20 milli Merck U/mL. The dilution-corrected limit of detection for the Type 6 cLIA was 4.2 milli Merck U/mL.
    measure
    Number of Participants Who Seroconvert to Human Papillomavirus (HPV) Type 6
    time Frame
    Month 7 (1 month postdose 3 in study Phase A)
  2. description
    Seroconversion was defined as achieving an anti-HPV Type 11 cLIA level of \>=16 milli Merck U/mL. The dilution-corrected limit of detection for the Type 11 cLIA was 3.9 milli Merck U/mL.
    measure
    Number of Participants Who Seroconvert to HPV Type 11
    time Frame
    Month 7 (1 month postdose 3 in study Phase A)
  3. description
    Seroconversion was defined as achieving an anti-HPV Type 16 cLIA level of \>=20 milli Merck U/mL. The dilution-corrected limit of detection for the Type 16 cLIA was 9.7 milli Merck U/mL.
    measure
    Number of Participants Who Seroconvert to HPV Type 16
    time Frame
    Month 7 (1 month postdose 3 in study Phase A)
  4. description
    Seroconversion was defined as achieving an anti-HPV Type 18 cLIA level of \>=24 milli Merck U/mL. The dilution-corrected limit of detection for the Type 18 cLIA was 5.8 milli Merck U/mL.
    measure
    Number of Participants Who Seroconvert to HPV Type 18
    time Frame
    Month 7 (1 month postdose 3 in study Phase A)
  5. description
    Participants were prompted to report injection-site experiences of pain, erythema, or swelling and were also asked to report any other injection-site adverse experiences
    measure
    Number of Participants With Injection-site Adverse Experiences
    time Frame
    Up to Day 5 after any vaccination in study Phase A
  6. measure
    Number of Participants With Elevated Temperature (Oral Temperature >=100 °F)
    time Frame
    Up to Day 5 after any vaccination in study Phase A
  7. description
    A serious adverse experience is any adverse experience that results in death, is life threatening, results in persistent or significant disability/incapacity, results in or prolongs existing inpatient hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is another important medical event that may jeopardize the participant and may require medical or surgical intervention
    measure
    Number of Participants With Serious Adverse Experiences
    time Frame
    From the time of informed consent is signed through the last study visit (up to 19 months)
secondary Outcomes
  1. description
    Anti-HPV Type 6 antibodies were measured by cLIA. The seropositive cut-off threshold for this assay is defined as 20 milli Merck U/mL.
    measure
    Geometric Mean Titer (GMT) of Anti-HPV Type 6 Antibody
    time Frame
    Month 7 (1 month postdose 3 in study Phase A)
  2. description
    Anti-HPV Type 11 antibodies were measured by cLIA. The seropositive cut-off threshold for this assay is defined as 16 milli Merck U/mL.
    measure
    GMT of Anti-HPV Type 11 Antibody
    time Frame
    Month 7 (1 month postdose 3 in study Phase A)
  3. description
    Anti-HPV Type 16 antibodies were measured by cLIA. The seropositive cut-off threshold for this assay is defined as 20 milli Merck U/mL.
    measure
    GMT of Anti-HPV Type 16 Antibody
    time Frame
    Month 7 (1 month postdose 3 in study Phase A)
  4. description
    Anti-HPV Type 18 antibodies were measured by cLIA. The seropositive cut-off threshold for this assay is defined as 24 milli Merck U/mL.
    measure
    GMT of Anti-HPV Type 18 Antibody
    time Frame
    Month 7 (1 month postdose 3 in study Phase A)
Full study description
brief Summary
The study is designed to determine the safety, tolerability and immunogenicity of a 3-dose regimen of GARDASIL™ administered to healthy females between 9 and 26 years of age, in Sub-Saharan Africa. Data from the current study are needed in order to complement existing extensive safety data from the GARDASIL™ clinical trials program, and confirm that GARDASIL™ may be administered safely and will induce immune responses in populations from and living in Sub-Saharan Africa, as GARDASIL™ has not previously been studied in this region of the world.
detailed Description
In Phase A of the study, healthy females between 9 and 12 years of age will be randomized (4:1) to receive the 3-dose regimen of GARDASIL™ or placebo, and those between 13 and 26 years old will receive GARDASIL™. In Phase B of the study, participants who received placebo in Phase A will have the option to receive the 3-dose regimen of GARDASIL™.
Source references
avail Ipds
references
  1. citation
    Mugo N, Ansah NA, Marino D, Saah A, Garner EI. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa. Hum Vaccin Immunother. 2015;11(6):1323-30. doi: 10.1080/21645515.2015.1008877.
    pmid
    25912475
    type
    RESULT
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-3e91417f9d2cdef745c5
      requested nct id
      NCT01245764
      primary nct id
      NCT01245764
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      9c84fe83f9fcdb12f3a6bb624863442db2afcee53df61c38a03e4f013f7f76a1
      payload sha256
      73bffb8e9ba0dfa07d5340019b9873e8619fe23ad8bdcaa3b6d153417553051c
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-3e91417f9d2cdef745c5
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01245764
      occurrences
      1. context exact
        NCT01245764
        end
        11
        exact text
        NCT01245764
        start
        0
      offset unit
      unicode_code_points
      query cond
      Vulvar Cancer
      query disease state id
      ds-vulvar-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-vulvar-cancer-000.json
      source file sha256
      9c84fe83f9fcdb12f3a6bb624863442db2afcee53df61c38a03e4f013f7f76a1
      source json pointer
      /studies/22/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      9b136a10d4a014aae70aacdeb01c8e34ed61bd18540aacc42710e3d397f803b1
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-878788a4dca647d99d60
      requested nct id
      NCT01245764
      primary nct id
      NCT01245764
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      b6710ff985346052b92134d475e1f6f9b2a9bbb7c87d1a3d83093a5921deff50
      payload sha256
      76ac7a7bfe8427f3ed571e1482dc56738223c1a4cfe73948b5c9349cbc8ad983
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-878788a4dca647d99d60
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01245764
      occurrences
      1. context exact
        NCT01245764
        end
        11
        exact text
        NCT01245764
        start
        0
      offset unit
      unicode_code_points
      query cond
      Vaginal Cancer
      query disease state id
      ds-vaginal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-vaginal-cancer-000.json
      source file sha256
      b6710ff985346052b92134d475e1f6f9b2a9bbb7c87d1a3d83093a5921deff50
      source json pointer
      /studies/33/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      9b136a10d4a014aae70aacdeb01c8e34ed61bd18540aacc42710e3d397f803b1

    Preserved source evidence · Not medical advice